Address
304 North Cardinal St.
Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
The immune microenvironment: a key to better treatments
Immunotherapy is revolutionizing cancer treatment, but its success in AML has been limited. The TALETE project is tackling this challenge by focusing on how the immune microenvironment responds to azacitidine and venetoclax, two frontline treatments for AML. Central to our research are pathways like AHR and IFN-γ, and their regulation by IDO1, a molecule that promotes immune suppression and tumor survival.
What we are investigating
By analyzing blood and urine samples, TALETE researchers measure key biomarkers of IDO1 activity, such as kynurenine levels. These markers are correlated with the composition of the BM microenvironment and immune cell activity. Advanced computational biology techniques help us deconvolute immune cell interactions, revealing how AML evades immune responses.
The impact
These insights will enable us to pinpoint why some patients respond to treatment while others do not. With this knowledge, we aim to develop strategies that enhance immune responses, potentially turning immunotherapy into a game-changer for AML patients.